tbuckley/cabot-search huggingface dataset:
YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling
Authors: Grace E. Coggins, Alvin Farrel, Komal S. Rathi, Colin M. Hayes, Laura Scolaro, Jo Lynne Rokita, John M. Maris
Journal: Cancer Research (2019)

Abstract Relapsed neuroblastomas are enriched with activating mutations of the RAS–MAPK signaling pathway. The MEK1/2 inhibitor trametinib delays tumor growth but does not sustain regression in neuroblastoma preclinical models. Recent studies have implicated the Hippo pathway transcriptional coactivator protein YAP1 as an additional driver of relapsed neuroblastomas, as well as a mediator of trametinib resistance in other cancers. Here, we used a highly annotated set of high-risk neuroblastoma cellular models to modulate YAP1 expression and RAS pathway activation to test whether increased YAP1 transcriptional activity is a mechanism of MEK1/2 inhibition resistance in RAS-driven neuroblastomas. In NLF (biallelic NF1 inactivation) and SK-N-AS (NRAS Q61K) cell lines, trametinib caused a near-complete translocation of YAP1 protein into the nucleus. YAP1 depletion sensitized neuroblastoma cells to trametinib, while overexpression of constitutively active YAP1 protein induced trametinib resistance. Mechanistically, significant enhancement of G1–S cell-cycle arrest, mediated by depletion of MYC/MYCN and E2F transcriptional output, sensitized RAS-driven neuroblastomas to trametinib following YAP1 deletion. These findings underscore the importance of YAP activity in response to trametinib in RAS-driven neuroblastomas, as well as the potential for targeting YAP in a trametinib combination. Significance: High-risk neuroblastomas with hyperactivated RAS signaling escape the selective pressure of MEK inhibition via YAP1-mediated transcriptional reprogramming and may be sensitive to combination therapies targeting both YAP1 and MEK.
Optimal Conditioning for Older Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Propensity Score Analysis
Authors: Stefan O. Ciurea, Ankur Varma, Piyanuch Kongtim, Samer Srour, Qaiser Bashir, Amin M. Alousi, Rohtesh S. Mehta, Betul Oran, Uday Popat, Chitra Hosing, Gabriela Rondon, Julianne Chen, Amanda L. Olson, Marina Y Konopleva, Richard E Champlin
Journal: Blood (2019)
Germinal Predisposition in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction: Identification of Deleterious Variants in Microsatellite Instability Genes
Authors: Tzu Hua Chen-Liang, Ana M Hurtado López, María Zurdo, Esperanza Such, Raul Teruel-Montoya, Laura Palomo, María-José Jimenez, Rafael Andres del Orbe Barreto, Blanca Navarro, Félix López Cadenas, Eduardo José Salido, Carmen Benet, Begoña Muiña, Raquel de Oña, Nuria de Haro, Fernando Ramos, Montserrat Arnan Sangerman, Francisca Maria Hernandez, Francisco José Ortuño, Leonor Senent, Ana Vicente, María Díez-Campelo, Maria Lourdes Hermosin, Teresa Bernal Del Castillo, Mar Tormo, Beatriz Arrizabalaga, Blanca Xicoy, José Cervera, Francesc Sole, Guillermo F. Sanz, Andres Jerez
Journal: Blood (2019)
Development of anti-angiogenic cancer vaccine using epitope peptides derived from vascular endothelial growth factor receptor 1 (VEGFR1)
Authors: Hidenobu Ishizaki, Takuya Tsunoda, Satoshi Wada, Masabumi Shibuya, Hideaki Tahara
Journal: Cancer Research (2006)

1404  The administration of the agents to prevent tumor angiogenesis has been shown by the recent clinical trials to be a valid option to treat various types of cancer. These agents include specific inhibitors and antibodies to block the VEGF-VEGFR system. However, these anti-angiogenic agents have significant limitations in specificity and the necessity for frequent administration. To overcome such shortcomings of the existing agents, we have been investigating the possibility of developing vaccination strategy to prevent tumor angiogenesis using epitope peptides derived from VEGFR2 and have successfully shown in mouse tumor model that it is a promising strategy. Furthermore, cancer vaccine targeting tumor endothelial cells rather than tumor cell themselves could also be effective for treating tumor cell variants which have lost their HLA class I expression, since endothelial cells do not down regulate HLA class I molecules in any conditions. In this study, we have focused on VEGFR1 which has been identified to be overexpressed on the endothelial cells of vessels in tumor but not in normal tissue. As the initial step, we identified HLA-A*0201 restricted epitope peptides derived from VEGFR1 using reverse immunology method. Based on the binding motif to the HLA-A*0201, epitope candidate peptides were predicted from their binding affinity. Then, we examined the effects of vaccination with these epitope candidate peptides in A2/Kb transgenic mice (A2/Kb TGM). Since A2/Kb TGM express α1 and α2 domains of human HLA-A*0201, they are useful in analyzing human CTL responses. Immunization to A2/Kb transgenic mice with identified epitope peptides induced CTL responses including increased IFN-γ secretion detectable with ELISPOT assay and potent cytotoxicity. Furthermore, immunization with these epitope peptides showed significant suppression of tumor-induced angiogenesis measured with in vivo dorsal air sac assay. To construct tumor systems closely related to clinical settings, we transplanted syngeneic mouse tumor cells that were chemically induced in C57BL/6 mice (H-2Kb) not expressing HLA-A*0201 molecules. Immunization with these epitope peptides showed significant inhibition of tumor growth in multiple tumors. There were no apparent adverse effects in mice immunized with these epitope peptides. Moreover, stimulation using these epitope peptides could induce peptide-specific CTL clones from human peripheral blood mononuclear cells with HLA-A*0201 in vitro, and these CTL clones showed peptide-specific and potent cytotoxicity. These results, in vivo and in vitro, strongly suggest that VEGFR1 is another promising target for T cell mediated anti-angiogenic immunotherapy and warrant further clinical development.
Longer Training for Radiographers
Authors: J. S. MacDonald, R. G. Grainger, A. H. Isaacson, D. C. Bernstein, P. A. W. Lea, P. Purcell, M. L. Thomas, B. Green, J. L. Morris, J. K. Davidson, W. B. James, K. W. M. Grossart, J. G. Sowerbutts
Journal: BMJ (1965)
EXTH-53. TUMOR TREATING FIELDS LEADS TO CHANGES IN MEMBRANE PERMEABILITY AND INCREASED PENETRATION BY ANTI-GLIOMA DRUGS
Authors: Edwin Chang, Chirag Patel, Corinne Beinat, Caroline Young, Thomas Flores, Yitian Zeng, Lydia Joubert, Hamed Arami, Arutselvan Natarajan, Robert Sinclair, Sanjiv Gambhir
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Efforts are underway to uncover novel, unorthodox therapies against glioblastoma (GBM). Tumor treating fields (TTFields) disrupt mitotic spindle formation and stymie proliferation in tumor cells. Combining TTFields with Withaferin A, synergistically inhibited proliferation in GBM. We wished to uncover the relevant mechanism. METHODS Human and murine GBM cells (GBM2, GBM39, U87-MG, KR158B) were isolated from primary tumors. Cells were engineered to stably express firefly luciferase (fLuc). Proliferation was assessed by bioluminescence imaging (using D-Luciferin as a substrate for fLuc) or cell counting. Dextran-FITC binding and scanning electron microscopy (SEM) studies were used to probe effects on cellular membranes. RESULTS TTFields (200 kHz, 4 V/cm) significantly inhibited growth of cells (n=3/time point, p≤0.02; 2-way ANOVA, no TTFields vs. TTFields). Combination of Withaferin A with TTFields significantly inhibited growth of glioma cells synergistically beyond that of Withaferin A or TTFields alone (p&lt; 0.01, at least n=3 experiments). Bioluminescence imaging suggested alterations in membrane configuration when cancer cells were exposed to TTFields. This was validated with observations of greater fluorescence of membrane-associating Dextran-FITC to U87-MG cells that were subjected to TTFields (p&lt; 0.01, 2-way ANOVA, TTFields vs. no TTFields, n=3 experiments). SEM revealed significantly greater and larger number of holes on the membrane surface of TTFields-exposed U87-MG cancer cells (53.5±19.1 holes per field of view and mean size=240.6±91.7 nm2) compared to unexposed cells (23.9±11.0 holes per field of view and mean size=129.8±31.9 nm2, p&lt; 0.005: TTFields exposed vs. non-exposed, n=3 samples, univariate Mann-Whitney test). CONCLUSION The findings suggest a novel combinatorial approach to treat GBM in a manner that is better than single treatment (drug or TTFields) alone and that is synergistic. Synergy is achieved through TTFields inducing increased permeability on membranes thus conferring greater accessibility to drug. Such a strategy is thus a promising candidate for future clinical translation in glioblastoma.
Effective Implementation of a Structured Protocol for Facilitation of the Judicious Use of Antibody Test for Diagnosis of Heparin Induced Thrombocytopenia
Authors: Somedeb Ball, Nimesh Adhikari, Anita Sultan, Kyaw Zin Thein, Khatrina Swarup, Meda Srikala, Francis Mogollon Duffo, Shabnam Rehman, Lukman Tijani, Sriman Swarup
Journal: Blood (2019)
REPORTS OF SOCIETIES
Authors: W N MASCALL, A J KING
Journal: BMJ (1947)

The Medical Society of the L.C.C. Service held a meeting at Horton Hospital, Epsom, on July 2, to discuss the modern treatment of syphilis.Dr. W. N. MASCALL said that there was at present no standard treatment of early syphilis; the dosage of penicillin appeared to vary between 2j and 16 million units; in some cases this was supported-by arsenic and bismuth, and in others it was-not.He still preferred the seven-and-a-half-day course of 2,400,000 units by divided dosage, but if the patient could not stay in hospital he gave one daily injection of 500,000 units in ethyl oleate for ten days.Following either of these courses, ten weekly injections of neo-arsphenamine 0.6 g. and bismuth oxychloride 0.4 g. were given.Further treatment depended on the serological changes in the blood and cerebrospinal fluid.Mr. A. J. KING opened the discussion on the treatment of late syphilis, excluding neurosyphilis and cardiovascular syphilis.Such cases were of two types-those with gummata and those termed " late latent syphilis," in which the diagnosis was based on positive serum reactions.The aims of treatment were to heal lesions, to render the patient non-infectious, and to prevent the development of fresh lesions."Cure'" in the sense of
The quality and safety of locum doctors: a narrative review
Authors: Jane Ferguson, Kieran Walshe
Journal: Journal of the Royal Society of Medicine (2019)

Locum doctors are often perceived to present greater risks of causing harm to patients than permanent doctors. After eligibility and quality assessment, eight empirical and 34 non-empirical papers were included in a narrative synthesis to establish what was known about the quality and safety of locum medical practice. Empirical literature was limited and weak methodologically. Locums enabled healthcare organisations to maintain appropriate staffing levels and allowed staffing flexibility, but they also gave rise to concerns about continuity of care, patient safety, team function and cost. There was some evidence to suggest that the way locum doctors are recruited, employed and used by organisations, may result in a higher risk of harm to patients. A better understanding of the quality and safety of locum working is needed to improve the use of locum doctors and the quality and safety of patient care that they provide.
Association Between Recreational Marijuana Legalization in the United States and Changes in Marijuana Use and Cannabis Use Disorder From 2008 to 2016
Authors: Magdalena Cerdá, Christine Mauro, Ava Hamilton, Natalie S. Levy, Julián Santaella-Tenorio, Deborah Hasin, Melanie M. Wall, Katherine M. Keyes, Silvia S. Martins
Journal: JAMA Psychiatry (2019)

Little is known about changes in marijuana use and cannabis use disorder (CUD) after recreational marijuana legalization (RML).To examine the associations between RML enactment and changes in marijuana use, frequent use, and CUD in the United States from 2008 to 2016.This survey study used repeated cross-sectional survey data from the National Survey on Drug Use and Health (2008-2016) conducted in the United States among participants in the age groups of 12 to 17, 18 to 25, and 26 years or older.Multilevel logistic regression models were fit to obtain estimates of before-vs-after changes in marijuana use among respondents in states enacting RML compared to changes in other states.Self-reported past-month marijuana use, past-month frequent marijuana use, past-month frequent use among past-month users, past-year CUD, and past-year CUD among past-year users.The study included 505 796 respondents consisting of 51.51% females and 77.24% participants 26 years or older. Among the total, 65.43% were white, 11.90% black, 15.36% Hispanic, and 7.31% of other race/ethnicity. Among respondents aged 12 to 17 years, past-year CUD increased from 2.18% to 2.72% after RML enactment, a 25% higher increase than that for the same age group in states that did not enact RML (odds ratio [OR], 1.25; 95% CI, 1.01-1.55). Among past-year marijuana users in this age group, CUD increased from 22.80% to 27.20% (OR, 1.27; 95% CI, 1.01-1.59). Unmeasured confounders would need to be more prevalent in RML states and increase the risk of cannabis use by 1.08 to 1.11 times to explain observed results, indicating results that are sensitive to omitted variables. No associations were found among the respondents aged 18 to 25 years. Among respondents 26 years or older, past-month marijuana use after RML enactment increased from 5.65% to 7.10% (OR, 1.28; 95% CI, 1.16-1.40), past-month frequent use from 2.13% to 2.62% (OR, 1.24; 95% CI, 1.08-1.41), and past-year CUD from 0.90% to 1.23% (OR, 1.36; 95% CI, 1.08-1.71); these results were more robust to unmeasured confounding. Among marijuana users in this age group, past-month frequent marijuana use and past-year CUD did not increase after RML enactment.This study's findings suggest that although marijuana legalization advanced social justice goals, the small post-RML increase in risk for CUD among respondents aged 12 to 17 years and increased frequent use and CUD among adults 26 years or older in this study are a potential public health concern. To undertake prevention efforts, further studies are warranted to assess how these increases occur and to identify subpopulations that may be especially vulnerable.
Feasibility of Outpatient High Dose Cytarabine in Patients with Acute Myeloid Leukemia
Authors: Chin-Hin NG, Xiaojuan Chen, Foong-Gwan Lee, Shi Hui Clarice Choong, Xiao-Shi Saw, Lon-Wann Sai, Michelle Poon, Hian Li Esther Hian Li Chan, Melissa Ooi, Yen Lin Chee, Yee Mei Lee
Journal: Blood (2019)
ACTR-59. A PHASE 1 STUDY OF BPM31510 PLUS VITAMIN K IN SUBJECTS WITH HIGH-GRADE GLIOMA THAT HAS RECURRED ON A BEVACIZUMAB-CONTAINING REGIMEN
Authors: Lawrence Recht, Reena Thomas, Sophie Bertrand, Priya Yerballa, Gordon Li, Michael Iv, Niven Narain, Rangaprasad Sarangarajan, Elder Granger, Seema Nagpal
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND High-grade gliomas (HGG) are characterized by dysregulated metabolism, utilizing glycolysis for energy production to support unrestricted growth. BPM 31510, an ubidecarenone (coenzyme Q10) containing lipid nanodispersion, causes a switch in cancer energy sourcing from glycolysis towards mitochondrial oxidative phosphorylation in vitro, reversing the Warburg effect and suggesting potential as an anti-tumor agent. The current study is a phase I study of BPM31510 + vitamin K in GB with tumor growth after bevacizumab (BEV). METHODS This is an open-label phase I study of BPM31510 continuous infusion with weekly vitamin K (10mg IM) in HGG patients using an mTPI design, starting at 110mg/kg, allowing for a single dose de-escalation and 2 dose-escalations. Patients had received first-line ChemoRadiation and were in recurrence following a BEV containing regimen. RESULTS 9 eligible and evaluable patients completed the 28 day DLT period. 8 patients had primary GB, 1 had anaplastic astrocytoma with confirmed pathologic transformation to GB. Median age was 55 years (27–67) and median KPS 70 (60–90) at enrollment. 4 patients were treated at the highest dose 171mg/kg, where there was a single DLT: Grade 3 AST &amp; ALT. The most common grade 1–2 AEs possibly, probably or definitely related to drug were elevated AST, rash, and fatigue, each occurring in 3 patients. Median OS for 9 eligible/evaluable patients was 128 days (95% CI: 48–209) while PFS was 34 days (CI of mean 8.9). 3 patients are currently alive; 2 patients have survived &gt;1 year. PK/PD data are being processed and will be presented. CONCLUSION This study confirms that BPM 31510 + vitamin K is safe and feasible in treatment-refractory HGG patients. Though this study demonstrates safety at 171mg/kg, the proposed dose for future studies in GB, based on additional pre-clinical and non-GB clinical data is 88mg/kg.
Intraoperative Ventilation Strategies to Reduce Pulmonary Complications in Obese Patients—Reply
Authors: Marcelo Gama de Abreu, Marcus Schultz, Paolo Pelosi
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Comparison of whole exome sequencing and FoundationOne Heme sequencing panel as tools for precision oncology in paediatric patients with difficult-to-treat solid tumours
Authors: H. Nosková, S. Adamcová, D. Knoflíčková, K. Pál, A. Grioni, T. Horňáková, T. Merta, P. Múdry, Z. Pavelka, K. Vejmělková, J. Štěrba, O. Slabý
Journal: Annals of Oncology (2019)
Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)
Authors: Pau Abrisqueta, Eva González-Barca, Christelle M Ferra, Eduardo Ríos Herranz, Margarita Fernandez, Julio Delgado, Rafael Andreu, Jose Angel Hernandez-Rivas, Maria Jose Terol, Marcos González, Patricia Baltasar Tello, Javier de la Serna, Angel Ramirez Payer, Carmen Ballester, Carol Moreno, Jose A. Garcia-Marco, Raul Cordoba, Lucrecia Yanez San Segundo, Luis Felipe Casado Montero, Francesc Bosch
Journal: Blood (2019)
TMOD-10. PRE-CLINICAL IMAGING MODEL OF GLIOBLASTOMA PSEUDOPROGRESSION USING DUAL FERUMOXYTOL AND GADOLINIUM CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING
Authors: Ramon Barajas, Randall Woltjer, Seunggu Han, Leslie Muldoon, Edward Neuwelt
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Temozolomide-based chemoradiotherapy (CRT) mediated neuroinflammation (pseudoprogression; Psp) within glioblastoma (GBM) is manifested by progressive gadolinium enhancement on magnetic resonance imaging (Gd-MRI)1. Unfortunately, Gd-MRI cannot reliably differentiate Psp from growing GBM. Macrophage infiltration is a prominent component of Psp, and can be noninvasively assessed by 24 hour delayed ferumoxytol-enhanced MRI (Fe-MRI)2. We have demonstrated that dual Fe- to Gd-contrast mismatch ratio may be a specific metric for identifying Psp3. The purpose of our study was to develop and characterize a preclinical model that specifically replicates the imaging context of macrophage mediated Psp. METHODS Athymic rats bearing intracerebral patient derived xenografts (GBM-39 and GSC-827) or U-87 GBM cells were randomized to; 1) untreated control (N= 5), 2) CRT only (irradiation [5 Gy] and temozolomide [20 mg/kg, PO] (N=4), or 3) CRT with Amphotericin B (Amp B) (0.2 mg/kg, IP QD x 3–7 days) (N=8)4. Three day post-therapeutic Fe- (ferumoxytol, 25 mg/kg IV) and Gd-MRI was performed as well as 7 day post-therapy Gd-MRI (N=7). Semi-automated enhancement segmentation and volume calculation was performed with Horos software5. Significance was evaluated using Students T-test with unequal variances. RESULTS The ratio of Fe- to Gd-enhancement volume 3 days after therapy was found to be significantly elevated within the CRT with Amp B group (1.7 ± 0.53) when compared to the CRT alone (0.62 ± 0.11) and control groups (0.43 ± 0.11); P&lt; 0.01. Seven days after therapy, Gd-enhancement volume was significantly decreased within the CRT with Amp B group (0.87 ± 0.13) when compared to CRT alone (0.38 ± 0.04; P&lt; 0.01), confirming treatment efficacy. CONCLUSION Preliminary results suggest that CRT combined with Amp B in this rat model replicates the imaging characteristics of human Psp and may result in improved efficacy3. Fe-MRI enhancement may capture the efficacious macrophage modulatory effects of Amp B.
Optimal sunscreen use allows vitamin D synthesis
Authors: A.R. Young, J. Narbutt, G.I. Harrison, K.P. Lawrence, M. Bell, C. O'Connor, P. Olson, K. Grys, K.A. Baczynska, M. Rogowski‐Tylman, H.C. Wulf, A. Lesiak, P.A. Philipsen
Journal: British Journal of Dermatology (2019)

Vitamin D, vital for bone health, is produced by the skin in response to ultraviolet radiation (UVR) from sunlight. However, as well as being the main source of vitamin D, UVR is a major cause of skin cancer. This has led to questions about how to prevent low levels of vitamin D whilst limiting the risk of skin cancer. This study, led by researchers from King's College London, found that use of sunscreen did not prevent most people from getting enough vitamin D whilst on a week‐long holiday to an area with a very high UV index. Whilst on holiday, 20 people received a broad‐spectrum sunscreen with a Sun Protection Factor (SPF) of 15, offering UVB protection and high UVA protection. Another 20 received a non‐broad‐spectrum sunscreen, also SPF 15 but with low UVA protection. These two groups were told how to use their sunscreens correctly to achieve the labelled SPF. In contrast, 22 people used their own sunscreen with no instructions on application, and 17 people formed a control group who remained in Poland. Blood samples were taken from participants 24 hours before and 24 to 48 hours after the holiday to check vitamin D levels. The first two groups saw a highly significant improvement in vitamin D levels. The group that used their own sunscreens also had significant vitamin D synthesis, but all had sunburn. During the same period, the control group had a slight decline in vitamin D.
Rituximab for Desensitization during HLA-Mismatched Stem Cell Transplantation in Patients with a Positive Donor Specific Anti-HLA Antibody: A Prospective Study
Authors: Ying-Jun Chang, Lan-Ping Xu, Yu Wang, Xiao-Hui Zhang, Huan Chen, Yu-Hong Chen, Feng-Rong Wang, Wei Han, Yu-Qian Sun, Chenhua Yan, Fei-Fei Tang, Ming-Rui Huo, Xiao-Dong Mo, Xiang-Yu Zhao, Kai-yan Liu, Xiao-Jun Huang
Journal: Blood (2019)
Prevalence and the Impact of Hypogammaglobulinemia in Newly Diagnosed, Untreated Diffuse Large B Cell Lymphoma
Authors: Namrata Singh, Sarah L Mott, Ashley Noel McCarthy, Sergei Syrbu, Thomas M. Habermann, Andrew L. Feldman, Susan L Slager, Grzegorz Nowakowski, Thomas E. Witzig, Umar Farooq, James R. Cerhan, Zuhair Ballas, Brian K. Link
Journal: Blood (2019)